The July 2020 AHPA Report includes AHPA goes virtual, postal service funding request, sustainability webinar on July 22, updated CA Prop 65 guidance, revised CITES primer, FTC proposed rule for 'Made in the USA,' and more.
Webinar presenters explain ways to ensure your marketing claims for herbal immune support products are substantiated, truthful and not misleading. Industry experts review several methods they’ve used to ensure their dietary supplement product claims are well substantiated, including: randomized, controlled clinical trials on a well-known elderberry product; in vitro testing to support the legitimacy of the product; and the relevance of use and training in substantiating the effectiveness of traditional Chinese herbal formulations.
Since the first week of March, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have been issuing warning letters alleging that marketers promoted a wide variety of products with claims to prevent, treat, mitigate, diagnose or cure COVID-19.
AHPA has analyzed 135 COVID-19 related warning letters issued by either FDA or FTC or by the agencies jointly between March 6, 2020, and May 11, 2020, and made available in each agency’s coronavirus information center as of May 15, 2020.
I am reaching out today to let you know that all AHPA activities normally held as in-person meetings will instead be produced as virtual events, webinars or teleconferences for the balance of 2020.
This free webinar provides practical information on how best to resume post-quarantine business operations while protecting your workforce. Learn what personal protective equipment and workspace adaptations should be implemented and how to manage ongoing business risks and liabilities. Additionally, hear from experts about how to be proactive and search for, and then correct, workplace conditions that could increase risk of COVID-19 infections.
Updated in May 2020, this free primer helps members and the herbal products industry understand the processes and practices that must be followed to comply with CITES requirements when importing and exporting species listed on CITES appendices
The June 2020 AHPA Report includes snapshots of global COVID-19 responses that impact the international supplement industry, FDA & FTC COVID-19 warning letters target social media and intravenous therapies, RFP for slippery elm sustainable wild harvest study, updated Hemp-CBD Status Report, and more.
This webinar provides guidance and practical tips on how to successfully market your hemp-derived products consistent with the requirements of the FDA and FTC. An FTC representative provides FTC’s perspective, summarizes recent enforcement actions, and discusses the level of substantiation respondents in those actions possessed or did not possess. Industry attorneys address legal standards, today’s ever-evolving regulatory environment, and the lawsuit risks and liabilities marketers of hemp products face.
2021 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.